USD
+$0.00
(+0.00%
)At Close (As of Sep 25, 2025)
$155.87M
Market Cap
-
P/E Ratio
-0.19
EPS
$3.40
52 Week High
$1.12
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $65M |
| Total Revenue | $86M |
| Cost Of Revenue | $20M |
| Costof Goods And Services Sold | $20M |
| Operating Income | $8.2M |
| Selling General And Administrative | $15M |
| Research And Development | $17M |
| Operating Expenses | $57M |
| Investment Income Net | - |
| Net Interest Income | -$9M |
| Interest Income | $1.5M |
| Interest Expense | $10M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $2.8M |
| Income Before Tax | -$6.3M |
| Income Tax Expense | $2M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$8.3M |
| Comprehensive Income Net Of Tax | - |
| Ebit | $4.1M |
| Ebitda | $6.9M |
| Net Income | -$8.3M |
| Field | Value (USD) |
|---|---|
| Total Assets | $53M |
| Total Current Assets | $44M |
| Cash And Cash Equivalents At Carrying Value | $5.9M |
| Cash And Short Term Investments | $5.9M |
| Inventory | $5.3M |
| Current Net Receivables | $16M |
| Total Non Current Assets | $9.4M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $7.6M |
| Intangible Assets Excluding Goodwill | $7.6M |
| Goodwill | - |
| Investments | - |
| Long Term Investments | $214K |
| Short Term Investments | $3.7M |
| Other Current Assets | $13M |
| Other Non Current Assets | - |
| Total Liabilities | $79M |
| Total Current Liabilities | $37M |
| Current Accounts Payable | $6.3M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $3.9M |
| Total Non Current Liabilities | $42M |
| Capital Lease Obligations | $1.2M |
| Long Term Debt | $41M |
| Current Long Term Debt | $3.5M |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $46M |
| Other Current Liabilities | $27M |
| Other Non Current Liabilities | $21K |
| Total Shareholder Equity | -$25M |
| Treasury Stock | - |
| Retained Earnings | -$417M |
| Common Stock | $364M |
| Common Stock Shares Outstanding | $49M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | $2.4M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $2.8M |
| Capital Expenditures | $1.5M |
| Change In Receivables | - |
| Change In Inventory | $785K |
| Profit Loss | - |
| Cashflow From Investment | $942K |
| Cashflow From Financing | -$21M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$8.3M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $65M |
| Total Revenue | $86M |
| Cost Of Revenue | $20M |
| Costof Goods And Services Sold | $20M |
| Operating Income | $8.2M |
| Selling General And Administrative | $15M |
| Research And Development | $17M |
| Operating Expenses | $57M |
| Investment Income Net | - |
| Net Interest Income | -$9M |
| Interest Income | $1.5M |
| Interest Expense | $10M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $2.8M |
| Income Before Tax | -$6.3M |
| Income Tax Expense | $2M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$8.3M |
| Comprehensive Income Net Of Tax | - |
| Ebit | $4.1M |
| Ebitda | $6.9M |
| Net Income | -$8.3M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Theratechnologies Inc. (THTX) is a Montreal-based biopharmaceutical company dedicated to developing and commercializing innovative therapies tailored to address significant unmet medical needs, particularly in the fields of HIV, oncology, and metabolic disorders. With a strategic focus on specialized drug delivery systems and targeted therapies, Theratechnologies aims to improve patient outcomes across North America and Europe. Boasting a robust pipeline of clinical and preclinical candidates, the company is well-positioned to leverage its expertise in biopharmaceutical development to enhance its market presence and drive sustainable growth.